How glucagon-like peptide 1 receptor agonists work
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
How glucagon-like peptide 1 receptor agonists work. / Andreasen, Christine Rode; Andersen, Andreas; Knop, Filip Krag; Vilsbøll, Tina.
I: Endocrine Connections, Bind 10, Nr. 7, 2021, s. R200-R212.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - How glucagon-like peptide 1 receptor agonists work
AU - Andreasen, Christine Rode
AU - Andersen, Andreas
AU - Knop, Filip Krag
AU - Vilsbøll, Tina
PY - 2021
Y1 - 2021
N2 - In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk and renal complications in high-risk individuals with T2D. These findings have changed guidelines on T2D management over the last years, and GLP-1RAs are now widely used in overweight patients with T2D as well as in patients with T2D and cardiovascular disease regardless of glycaemic control. The currently available GLP-1RAs have different pharmacokinetic profiles and differ in their ability to improve glycaemia, reduce body weight and in their cardio-and renal protective potentials. Understanding how these agents work, including insights into their pleiotropic effects on T2D pathophysiology, may improve their clinical utilisation and be useful for exploring other indications such as non-alcoholic steatohepatitis and neurodegenerative disorders. In this review, we provide an overview of approved GLP-1RAs, their clinical effects and mode of action, and we offer insights into the potential of GLP-1RAs for other indications than T2D. Finally, we will discuss the emerging data and therapeutic potential of using GLP-1RAs in combinations with other receptor agonists.
AB - In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk and renal complications in high-risk individuals with T2D. These findings have changed guidelines on T2D management over the last years, and GLP-1RAs are now widely used in overweight patients with T2D as well as in patients with T2D and cardiovascular disease regardless of glycaemic control. The currently available GLP-1RAs have different pharmacokinetic profiles and differ in their ability to improve glycaemia, reduce body weight and in their cardio-and renal protective potentials. Understanding how these agents work, including insights into their pleiotropic effects on T2D pathophysiology, may improve their clinical utilisation and be useful for exploring other indications such as non-alcoholic steatohepatitis and neurodegenerative disorders. In this review, we provide an overview of approved GLP-1RAs, their clinical effects and mode of action, and we offer insights into the potential of GLP-1RAs for other indications than T2D. Finally, we will discuss the emerging data and therapeutic potential of using GLP-1RAs in combinations with other receptor agonists.
KW - diabetes
KW - cardiovascular
KW - metabolism
KW - inflammation
KW - obesity
KW - ONCE-DAILY LIRAGLUTIDE
KW - METFORMIN-TREATED PATIENTS
KW - INCRETIN-BASED THERAPIES
KW - OPEN-LABEL
KW - CARDIOVASCULAR OUTCOMES
KW - GLYCEMIC CONTROL
KW - INSULIN-TREATMENT
KW - WEEKLY EXENATIDE
KW - GLP-1 RECEPTORS
KW - DOUBLE-BLIND
U2 - 10.1530/EC-21-0130
DO - 10.1530/EC-21-0130
M3 - Review
C2 - 34137731
VL - 10
SP - R200-R212
JO - Endocrine Connections
JF - Endocrine Connections
SN - 2049-3614
IS - 7
ER -
ID: 275530662